WESTERVILLE, Ohio, May 7, 2026, 19:02 EDT
agilon health shares surged, more than doubling on Thursday, after the Medicare-focused physician platform turned in a first-quarter profit that topped estimates, boosted its 2026 forecast, and finally delivered investors a clean earnings beat following a turbulent period. The stock was recently at $60.66, a jump of $32.79 from the previous close, and had earlier hit $63.75.
This shift comes as agilon welcomes its new CEO, Tim O’Rourke, with the company at a crossroads—facing pressure to show that fewer members don’t have to mean worse numbers. O’Rourke steps into the role as of May 7, following Ronald A. Williams, who stays on as chairman.
The bigger issue here is medical cost control. agilon partners with physician groups using value-based care—a model that pays for keeping costs down and improving results, not for running up visits and procedures. Investors have been pushing healthcare firms linked to Medicare Advantage, the privately managed Medicare coverage for seniors and some disabled Americans, to prove their pricing and care management can keep pace with rising service use. CVS Health just bumped up its 2026 outlook the day before, crediting tighter cost control at its Aetna insurance business.
agilon posted a 7% drop in first-quarter revenue, down to $1.42 billion from $1.53 billion last year, as the company saw membership slip following exits from certain markets and payers. Net income, however, surged to $49 million from $12 million. Adjusted EBITDA climbed as well, hitting $54 million compared to $21 million a year ago.
The company bumped up its outlook for the year, forecasting 2026 revenue between $5.68 billion and $5.81 billion. Adjusted EBITDA is now projected in a $10 million to $40 million range, a sharp shift from its earlier view that spanned a $15 million loss to a $15 million gain.
Ronald A. Williams, agilon’s executive chairman, pointed to “disciplined execution” in the quarter and cited “early returns” on the company’s bets in data, technology and clinical initiatives. Williams added that O’Rourke is expected to tighten up execution and speed up agilon’s shift “from action to outcome.” Business Wire
Membership numbers remain down. As of March 31, agilon counted 536,000 members on its platform—an 11% drop from the prior year. That figure includes 426,000 enrolled in Medicare Advantage and 110,000 under the ACO model. ACO REACH, the company’s Medicare care model, lets providers take on some of the risk—and rewards—based on patient costs and care quality.
Wall Street wasted no time reacting. Jefferies analyst Jack Slevin bumped agilon up to Buy from Hold, lifting his price target all the way to $48—up from $27.50. Slevin pointed to clearer trends and “supportive Medicare Advantage rates” for 2026 and 2027. Jefferies flagged that 85% of lives now flow through agilon’s data pipeline—investors took that as a signal of tighter visibility into claims and risk scores. Investing.com
Deutsche Bank’s George Hill shifted his rating on agilon to Buy, bumping the price target to $49 from $33, Benzinga said. Barron’s noted Hill pointed to agilon’s boosted EBITDA outlook, a better environment, and valuation as reasons for the move.
The company remains heavily reliant on a narrow slice of business. Its 10-Q reveals that Medicare Advantage payers delivered “substantially all” of agilon’s first-quarter revenue, with a handful of big payers dominating the total. That’s a double-edged sword: stronger contracts can nudge margins higher, but a fight with a payer, sudden rate change, or jump in medical costs can bite hard and fast. Stock Titan
Legal questions still hang over agilon. In its latest quarterly filing, the company disclosed that a consolidated securities case is moving through discovery, with plaintiffs pointing to alleged misstatements from April 2021 through February 2024. At issue: financial guidance, medical margin, adjusted EBITDA, growth plans, and data management. Some of those claims got tossed in 2025, but others are still on track.
O’Rourke is pitching the job as one of execution, not marketing. When he took the helm, he pointed to agilon’s “distinct platform”—with upgrades in data, analytics, contracting, and cost management now in place to support results and expansion. Investors seem to be giving him some leeway, judging by the stock. But that doesn’t answer everything. Business Wire
